The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm

A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis

(2014) S. L. Etheridge et al.   BLOOD

JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation

(2014) R. Besancenot et al.   BLOOD

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

(2014) Neha Bhagwat et al.   BLOOD

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis

(2014) S. C. Meyer et al.   BLOOD

JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms

(2014) S. Leah Etheridge et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation

(2014) A. P. Ng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice

(2012) D. Yan et al.   BLOOD

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes

(2012) C. Pecquet et al.   BLOOD

New mutations and pathogenesis of myeloproliferative neoplasms

(2011) W. Vainchenker et al.   BLOOD

Mouse models of myeloproliferative neoplasms: JAK of all grades

(2011) J. Li et al.   Disease Models & Mechanisms

The Thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis

(2011) Fu-Sheng Chou et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis

(2011) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice

(2010) C. Marty et al.   BLOOD

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

(2010) H. Akada et al.   BLOOD

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential

(2009) D. G. Kent et al.   BLOOD

Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia

(2009) K. Liu et al.   HAEMATOLOGICA

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

(2008) G. Wernig et al.   BLOOD

Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis

(2008) B. J. Lannutti et al.   BLOOD

Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes

(2008) R. Tiedt et al.   BLOOD

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

(2008) A Tefferi et al.   LEUKEMIA

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

(2007) R. Tiedt et al.   BLOOD